Campbell & CO Investment Adviser LLC Invests $3.67 Million in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Campbell & CO Investment Adviser LLC acquired 29,592 shares of Jazz Pharmaceuticals PLC, valued at approximately $3.67 million, during the first quarter.
• Several institutional investors, including Dimensional Fund Advisors LP and Ameriprise Financial Inc., have increased their stakes in Jazz Pharmaceuticals, contributing to 89.14% of the company's stock being owned by institutional investors and hedge funds.
• Jazz Pharmaceuticals reported a loss of $8.25 per share in its latest earnings release, missing analysts' consensus estimates, although it had a revenue of $1.05 billion, matching expectations.

Campbell & CO Investment Adviser LLC bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 29,592 shares of the specialty pharmaceutical company's stock, valued at approximately $3,674,000.

A number of other large investors have also recently modified their holdings of JAZZ. MML Investors Services LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $1,785,000. Tower Research Capital LLC TRC boosted its holdings in shares of Jazz Pharmaceuticals by 238.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,025 shares of the specialty pharmaceutical company's stock valued at $373,000 after purchasing an additional 2,132 shares in the last quarter. State of Tennessee Department of Treasury boosted its holdings in shares of Jazz Pharmaceuticals by 5.8% in the 4th quarter. State of Tennessee Department of Treasury now owns 28,654 shares of the specialty pharmaceutical company's stock valued at $3,529,000 after purchasing an additional 1,568 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Jazz Pharmaceuticals by 26.7% during the 4th quarter. Hsbc Holdings PLC now owns 2,871 shares of the specialty pharmaceutical company's stock valued at $354,000 after acquiring an additional 605 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Jazz Pharmaceuticals by 2.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 38,184 shares of the specialty pharmaceutical company's stock valued at $4,703,000 after acquiring an additional 1,041 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 1.3%

NASDAQ:JAZZ traded up $1.64 during trading hours on Friday, hitting $127.77. 228,785 shares of the company were exchanged, compared to its average volume of 947,713. The stock has a market capitalization of $7.75 billion, a price-to-earnings ratio of -18.99, a price-to-earnings-growth ratio of 7.84 and a beta of 0.34. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a fifty day simple moving average of $114.07 and a 200 day simple moving average of $117.25.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on JAZZ. Royal Bank Of Canada raised their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a report on Thursday. Piper Sandler reissued an "overweight" rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a report on Thursday. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective on the stock. Finally, Robert W. Baird cut their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Thirteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $178.21.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.